Overall, our study demonstrated that widely used TB subunit vaccine Ags adjuvanted with TLR4 (MPL and GLA) and STING (CDG) agonists cooperatively and effectively elicited robust cellular immune responses, ultimately providing better long-term protective efficacy compared to using each adjuvant individually (Fig. 8). This evidence concerns the gene TLR4 and tuberculosis.